This inventor holds 39 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Cancer Immunotherapy. Top assignees: The University of Texas System, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Introgen Research Institute, Inc.. Active years: 1997-2025.
Company Filing History:
39 out of 5,622 
3 out of 3,688 
1 out of 1 Years Active: 1997-2025
Areas of Expertise:
Title: Jack A Roth: Pioneering Innovations in Cancer Therapy
Introduction:
Jack A Roth, a distinguished inventor based in Houston, Texas, has made significant contributions to the field of medicine through his groundbreaking patents and research endeavors. With 38 patents to his name, Roth's innovative work in cancer therapy and gene transfer technologies has garnered widespread acclaim within the scientific community.
Latest Patents:
Roth's recent patents showcase his focus on developing advanced methods and compositions for cancer therapy and non-viral gene therapy. One of his latest patents, titled "Methods and compositions for TUSC2 immunotherapy," highlights his approach to treating cancer by administering TUSC2 therapy in conjunction with immune checkpoint inhibitors. Additionally, his patent on "Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases" underscores his commitment to leveraging lipid formulations for efficient gene transfer in treating hyperproliferative conditions.
Career Highlights:
Throughout his career, Roth has been associated with esteemed institutions such as the University of Texas System and The Board of Regents of the University of Texas Systems. His innovative research initiatives and patents have not only advanced the field of medicine but have also paved the way for novel treatment modalities in cancer therapy and gene transfer technologies.
Collaborations:
Roth has had the privilege of collaborating with accomplished individuals in the scientific community, including coworkers such as Wei-Wei Zhang and Tapas Mukhopadhyay. These collaborations have played a pivotal role in furthering Roth's research objectives and have contributed to the development of cutting-edge therapies for various medical conditions.
Conclusion:
In conclusion, Jack A Roth's prolific career as an inventor and researcher epitomizes the essence of innovation in the realm of medical science. His unwavering dedication to advancing cancer therapy and gene transfer technologies underscores his status as a trailblazer in the field. Roth's patents and collaborative efforts serve as a testament to his enduring impact on the landscape of modern medicine, with far-reaching implications for the future of healthcare.